CDK4 and cancer: Other possible advantages of SKP2 as a therapeutic target in cancer include the potential for selective targeting compared with the use of other signaling inhibitors with broader activities or higher toxicity, such as the proteasomal inhibitor bortezomib [46] or the CDK4/6 inhibitors [47].